title: Oral citalopram and reboxetine challenge tests before and after selective antidepressant treatment.
authors.forename: Olaf
authors.initials: O
authors.lastname: Moeller
authors.forename: Guenter
authors.initials: G
authors.lastname: Hetzel
authors.forename: Matthias
authors.initials: M
authors.lastname: Rothermundt
authors.forename: Nikolaus
authors.initials: N
authors.lastname: Michael
authors.forename: Peter W
authors.initials: PW
authors.lastname: Nyhuis
authors.forename: Thomas
authors.initials: T
authors.lastname: Suslow
authors.forename: Volker
authors.initials: V
authors.lastname: Arolt
authors.forename: Andreas
authors.initials: A
authors.lastname: Erfurth
mesh_terms: D000928:Antidepressive Agents / Q000627:therapeutic use*; D015283:Citalopram / Q000008:administration & dosage / Q000494:pharmacology*; D003866:Depressive Disorder / Q000188:drug therapy*; D006801:Humans; D008995:Monoamine Oxidase / Q000378:metabolism; D009025:Morpholines / Q000008:administration & dosage / Q000494:pharmacology*; D011388:Prolactin / Q000378:metabolism*; D011446:Prospective Studies; D000077593:Reboxetine; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D013997:Time Factors
chemical_list: D000928:Antidepressive Agents; D015283:Citalopram; D008995:Monoamine Oxidase; D009025:Morpholines; D011388:Prolactin; D000077593:Reboxetine; D017367:Selective Serotonin Reuptake Inhibitors